Strategies to inhibit arsenic trioxide-induced cardiotoxicity in acute promyelocytic leukemia
- PMID: 30770558
- DOI: 10.1002/jcp.28292
Strategies to inhibit arsenic trioxide-induced cardiotoxicity in acute promyelocytic leukemia
Abstract
Objective: Arsenic trioxide (ATO) is a drug commonly used for the treatment of acute promyelocytic leukemia (APL). Although ATO has been shown to cause significant improvement in patients, it is associated with serious side effects, which sometimes lead to the patient's death. In this review paper, we examine the reports of ATO-induced cardiotoxicity in APL patients and evaluate the strategies to reduce the incidence of such toxicity.
Methods: The key search terms were "arsenic trioxide," "acute promyelocytic leukemia," "cardiotoxicity," "molecular pathway," and "biomarker."
Results: Studies have indicated the involvement of several molecular pathways in ATO-induced cardiotoxicity. These pathways increase the production of reactive oxygen species by interfering with intracellular calcium homeostasis as well as impairing the transfer of calcium into endoplasmic reticulum and mitochondria. On the other hand, increasing or decreasing expressions of some microRNAs (miRs) have been shown to play a role in cardiotoxicity.
Conclusion: Finally, it can be stated that given the essential role of molecular pathways in cardiotoxicity and considering the fact these pathways impair the regulation of miRs expression, identification of molecular pathways involved in ATO-induced cardiotoxicity aimed at targeting miRs could be a new therapeutic strategy to prevent cardiotoxicity.
Keywords: acute promyelocytic leukemia; arsenic trioxide; calcium; cardiotoxicity; microRNA.
© 2019 Wiley Periodicals, Inc.
References
REFERENCES
-
- Abad, M., Hashimoto, H., Zhou, H., Morales, M. G., Chen, B., Bassel-Duby, R., & Olson, E. N. (2017). Notch inhibition enhances cardiac reprogramming by increasing MEF2C transcriptional activity. Stem Cell Reports, 8(3), 548-560.
-
- Agustini, F. D., Arozal, W., Louisa, M., Siswanto, S., Soetikno, V., Nafrialdi, N., & Suyatna, F. (2016). Cardioprotection mechanism of mangiferin on doxorubicin-induced rats: Focus on intracellular calcium regulation. Pharmaceutical Biology, 54(7), 1289-1297.
-
- Arany, Z., He, H., Lin, J., Hoyer, K., Handschin, C., Toka, O., … Spiegelman, B. M. (2005). Transcriptional coactivator PGC-1α controls the energy state and contractile function of cardiac muscle. Cell Metabolism, 1(4), 259-271.
-
- Binu, P., Gifty, K., Vineetha, R., Abhilash, S., Arathi, P., & Nair, R. H. (2018). Eugenol, a plant-derived phenolic nutraceutical, protects thiol (SH) group in myocardium from ROS-mediated oxidation under chemotherapeutic stress induced by arsenic trioxide-a in vivo model study. Drug and Chemical Toxicology, 41, 352-357.
-
- Bocchi, L., Savi, M., Naponelli, V., Vilella, R., Sgarbi, G., Baracca, A., … Stilli, D. (2018). Long-term oral administration of theaphenon-E improves cardiomyocyte mechanics and calcium dynamics by affecting phospholamban phosphorylation and ATP production. Cellular Physiology and Biochemistry, 47(3), 1230-1243.
Publication types
LinkOut - more resources
Full Text Sources
